MannKind Management
Management criteria checks 2/4
MannKind's CEO is Michael Castagna, appointed in May 2017, has a tenure of 6.92 years. total yearly compensation is $7.07M, comprised of 9.9% salary and 90.1% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $3.70M. The average tenure of the management team and the board of directors is 6.8 years and 4.8 years respectively.
Key information
Michael Castagna
Chief executive officer
US$7.1m
Total compensation
| CEO salary percentage | 9.9% |
| CEO tenure | 6.9yrs |
| CEO ownership | 0.3% |
| Management average tenure | 6.8yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
This Just In: Analysts Are Boosting Their MannKind Corporation (NASDAQ:MNKD) Outlook for This Year
Mar 03
MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement
Mar 02MannKind's Tyvaso DPI Royalty Deal Signals Undervaluation
Feb 15MannKind Corporation's (NASDAQ:MNKD) Price Is Right But Growth Is Lacking
Jan 03Revenues Working Against MannKind Corporation's (NASDAQ:MNKD) Share Price
May 15MannKind Corporation's (NASDAQ:MNKD) Intrinsic Value Is Potentially 68% Above Its Share Price
Jan 27Mannkind Corporation: Ready For Your Biotech Portfolio
Sep 01New Forecasts: Here's What Analysts Think The Future Holds For MannKind Corporation (NASDAQ:MNKD)
Aug 19MannKind down 2% after Q2 2022 bottom line miss; however, net loss narrowed
Aug 09MannKind: What Do Pfizer, Sanofi, And MannKind Have In Common?
Feb 25MannKind: A Promising Player In The Inhalable Insulin Market
Feb 08US$6.17: That's What Analysts Think MannKind Corporation (NASDAQ:MNKD) Is Worth After Its Latest Results
Aug 14Lytham Partners Summer 2021 Investor Conference
Jun 14MannKind (MNKD) Investor Presentation - Slideshow
Jun 04MannKind reduces debt by $49.5M and restructures remaining obligations
Apr 26Did Business Growth Power MannKind's (NASDAQ:MNKD) Share Price Gain of 293%?
Feb 22MannKind to co-promote Thyquidity
Dec 17MannKind (MNKD) earns $12.5M milestone under licensing deal for treprostinil
Nov 20MannKind: Global Product Sales, Late-Stage Clinical Pipeline Candidate, And Strong Leadership, 34% Upside
Nov 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$7m | US$702k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$31m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$4m | US$623k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$98m |
| Jun 30 2022 | n/a | n/a | -US$88m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$4m | US$598k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$4m | US$495k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$45m |
| Jun 30 2020 | n/a | n/a | -US$44m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$2m | US$511k | -US$52m |
| Sep 30 2019 | n/a | n/a | -US$47m |
| Jun 30 2019 | n/a | n/a | -US$61m |
| Mar 31 2019 | n/a | n/a | -US$71m |
| Dec 31 2018 | US$2m | US$500k | -US$87m |
| Sep 30 2018 | n/a | n/a | -US$110m |
| Jun 30 2018 | n/a | n/a | -US$119m |
| Mar 31 2018 | n/a | n/a | -US$131m |
| Dec 31 2017 | US$1m | US$459k | -US$117m |
Compensation vs Market: Michael's total compensation ($USD7.07M) is above average for companies of similar size in the US market ($USD3.45M).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael Castagna (46 yo)
6.9yrs
Tenure
US$7,068,114
Compensation
Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.9yrs | US$7.07m | 0.34% $ 3.7m | |
| Chief Financial Officer | 6.8yrs | US$2.34m | 0.16% $ 1.8m | |
| Executive VP & COO | 1.1yrs | US$2.74m | 0.0048% $ 53.1k | |
| Executive VP | 22.3yrs | US$2.34m | 0.14% $ 1.5m | |
| Executive VP and Chief People & Workplace Officer | 7.3yrs | US$2.22m | 0.22% $ 2.4m | |
| Executive Vice President of Technical Operations | 1.5yrs | US$1.12m | 0.014% $ 152.1k | |
| VP of Investor Relations & Treasury | 6.8yrs | US$519.59k | no data | |
| Senior Vice President of Worldwide Regulatory Affairs | 18.5yrs | no data | no data | |
| Chief Commercial Officer | 6.8yrs | US$921.51k | no data | |
| Executive VP of Research & Development and Chief Medical Officer | less than a year | no data | 0.058% $ 639.5k |
6.8yrs
Average Tenure
58.5yo
Average Age
Experienced Management: MNKD's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.9yrs | US$7.07m | 0.34% $ 3.7m | |
| Independent Director | 20.5yrs | US$241.73k | 0.044% $ 479.6k | |
| Independent Director | 19.8yrs | US$240.64k | 0.098% $ 1.1m | |
| Independent Director | 5.4yrs | US$197.88k | 0.010% $ 112.1k | |
| Independent Director | 20.3yrs | US$200.38k | 0.0055% $ 60.5k | |
| Independent Director | 4.3yrs | US$200.38k | 0.065% $ 713.4k | |
| Independent Chairman | 8.9yrs | US$255.64k | 0.0090% $ 99.0k | |
| Independent Director | 3.3yrs | US$221.73k | 0.040% $ 433.5k | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Independent Director | 4.1yrs | US$192.88k | 0.041% $ 448.3k | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data |
4.8yrs
Average Tenure
67yo
Average Age
Experienced Board: MNKD's board of directors are considered experienced (4.8 years average tenure).